Propanc Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 12, 2025, and June 13, 2025. Propanc Biopharma, Inc., a Delaware corporation with its principal executive office in Camberwell, Australia, reported the entry into two material definitive agreements to secure working capital.
Key Financial Metrics and Agreements
The filing details two distinct financing instruments:
- Convertible Promissory Note (June 12, 2025):
- Principal Amount: $25,000 USD.
- Purchase Price: $22,500 USD (issued at a discount).
- Interest Rate: 8% per annum.
- Maturity Date: June 12, 2026.
- Conversion Terms: Convertible at $5.00 per share. Adjusts to $3.00 if stock trades below $4.00 for 5+ consecutive days. In default, converts at the lowest trading price.
- Prepayment Penalty: 110% of face value (first 60 days), increasing to 120% (61-120 days) and 125% (121-180 days). No prepayment right after 180 days.
- Board Member Loan (June 13, 2025):
- Principal Amount: $13,188 AUD.
- Interest Rate: 12% per annum (18% default rate).
- Maturity Date: June 30, 2025.
- Payment Terms: Interest payable monthly in arrears.
Liquidity and Debt: The filing does not provide current cash balances, total debt levels, or liquidity ratios. Proceeds from both instruments are designated for general working capital.
Material Changes and Unusual Items
The primary material change is the incurrence of new debt obligations totaling approximately $25,000 USD and $13,188 AUD. The Convertible Note includes unusual terms regarding prepayment penalties that increase over time and a "ratchet" conversion price that drops significantly in the event of a default or sustained low stock price, potentially leading to significant dilution.
Guidance, Risks, and Contingencies
Risks and Covenants:
- Default Triggers: The Note includes events of default such as failure to pay, failure to issue shares, failure to maintain OTC listing, or breach of reporting requirements. Default accelerates repayment and lowers the conversion price to the lowest trading price.
- Share Reserve: The Company must maintain a reserve of at least 500% of the number of Conversion Shares.
- Ownership Limitation: Conversions are subject to a 4.99% beneficial ownership limitation.
Management Commentary: Management intends to use net proceeds for general working capital. No specific financial guidance or outlook for future periods is provided in this filing.
Investor Verification Checklist
- Verify the current trading price of Propanc Biopharma common stock to assess the immediate dilution impact of the $5.00 conversion price.
- Confirm the Company's ability to maintain its OTC listing, as failure to do so constitutes an immediate event of default.
- Review the Company's cash runway to determine if the $13,188 AUD loan (due June 30, 2025) can be repaid or refinanced before maturity.
- Check for any existing defaults on prior notes issued to the same Investor, which would trigger default on this new Note.
- Examine the full text of the exhibits (4.1, 10.1, 10.2) for additional covenants not summarized in the 8-K.